1. Academic Validation
  2. AI-Powered Virtual Screening of Large Compound Libraries Leads to the Discovery of Novel Inhibitors of Sirtuin-1

AI-Powered Virtual Screening of Large Compound Libraries Leads to the Discovery of Novel Inhibitors of Sirtuin-1

  • J Med Chem. 2023 Aug 10;66(15):10241-10251. doi: 10.1021/acs.jmedchem.3c00128.
Anastasiia Gryniukova 1 Florian Kaiser 2 Iryna Myziuk 1 Diana Alieksieieva 1 Christoph Leberecht 2 Peter P Heym 3 Olga O Tarkhanova 4 Yurii S Moroz 4 5 Petro Borysko 1 V Joachim Haupt 2
Affiliations

Affiliations

  • 1 Enamine Ltd, 78 Chervonotkatska Str., 02094 Kyïv, Ukraine.
  • 2 PharmAI, Tatzberg 47, 01307 Dresden, Germany.
  • 3 Sum of Squares, Lange Straße 41, 04509 Delitzsch, Germany.
  • 4 Chemspace LLC, 85 Chervonotkatska Str., 03190 Kyïv, Ukraine.
  • 5 Taras Shevchenko National University of Kyïv, Volodymyrska Street 60, Kyïv 01601, Ukraine.
Abstract

The discovery of new scaffolds and chemotypes via high-throughput screening is tedious and resource intensive. Yet, there are millions of small molecules commercially available, rendering comprehensive in vitro tests intractable. We show how smart algorithms reduce large screening collections to target-specific sets of just a few hundred small molecules, allowing for a much faster and more cost-effective hit discovery process. We showcase the application of this virtual screening strategy by preselecting 434 compounds for Sirtuin-1 inhibition from a library of 2.6 million compounds, corresponding to 0.02% of the original library. Multistage in vitro validation ultimately confirmed nine chemically novel inhibitors. When compared to a competitive benchmark study for Sirtuin-1, our method shows a 12-fold higher hit rate. The results demonstrate how AI-driven preselection from large screening libraries allows for a massive reduction in the number of small molecules to be tested in vitro while still retaining a large number of hits.

Figures
Products